Literature DB >> 18417034

Tat-regulated expression of RNA interference: triggers for the treatment of HIV infection.

Hoshang Unwalla1, John J Rossi.   

Abstract

HIV infection is a lifelong problem requiring continual medication for suppressing viral replication. Current strategies of antiretroviral drug combinations have proven effective in prolonging the time from infection to the symptoms of AIDS. Nevertheless, chemotherapy is not without its problems, which include toxicities and eventual emergence of virus mutants that are resistant to current antiretrovirals. Gene therapy refers to the introduction of effector oligonucleotides to transiently or stably alter gene expression or the delivery and expression of an exogenous gene within a specific target cell. A number of studies have demonstrated effective silencing/inhibition of HIV-1 replication by using RNA-based effector oligonucleotides for RNA interference. In this study, we have taken advantage of lentiviral vector-mediated delivery of anti-HIV short hairpin RNA for the treatment of HIV infection in hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417034      PMCID: PMC2703456          DOI: 10.1007/s11904-008-0007-3

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  28 in total

1.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs.

Authors:  Rui Yi; Yi Qin; Ian G Macara; Bryan R Cullen
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

Review 2.  siRNA and miRNA: an insight into RISCs.

Authors:  Guiliang Tang
Journal:  Trends Biochem Sci       Date:  2005-02       Impact factor: 13.807

3.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing.

Authors:  Thimmaiah P Chendrimada; Richard I Gregory; Easwari Kumaraswamy; Jessica Norman; Neil Cooch; Kazuko Nishikura; Ramin Shiekhattar
Journal:  Nature       Date:  2005-06-22       Impact factor: 49.962

4.  Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein.

Authors:  Hoshang J Unwalla; Hai-Tang Li; Ingrid Bahner; Ming-Jie Li; Donald Kohn; John J Rossi
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 6.  Common mechanisms for the control of eukaryotic transcriptional elongation.

Authors:  A Krumm; T Meulia; M Groudine
Journal:  Bioessays       Date:  1993-10       Impact factor: 4.345

7.  Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA.

Authors:  Hoshang J Unwalla; Ming-Jie Li; James D Kim; Hai Tang Li; Ali Ehsani; Jessica Alluin; John J Rossi
Journal:  Nat Biotechnol       Date:  2004-11-28       Impact factor: 54.908

Review 8.  Cellular control of gene expression by T-type cyclin/CDK9 complexes.

Authors:  Judit Garriga; Xavier Graña
Journal:  Gene       Date:  2004-08-04       Impact factor: 3.688

9.  Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway.

Authors:  J R Kennerdell; R W Carthew
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

10.  Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells.

Authors:  Peter C Scacheri; Orit Rozenblatt-Rosen; Natasha J Caplen; Tyra G Wolfsberg; Lowell Umayam; Jeffrey C Lee; Christina M Hughes; Kalai Selvi Shanmugam; Arindam Bhattacharjee; Matthew Meyerson; Francis S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

View more
  1 in total

Review 1.  RNAi and small interfering RNAs in human disease therapeutic applications.

Authors:  Monica R Lares; John J Rossi; Dominique L Ouellet
Journal:  Trends Biotechnol       Date:  2010-09-15       Impact factor: 19.536

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.